SINORDA BIOMEDICINE
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SINORDA BIOMEDICINE - overview
Established
2010
Location
Guiyang, Guizhou, China
Primary Industry
Biotechnology
About
Founded in 2010 and based in Guiyang, China, SINORDA BIOMEDICINE is a clinical-stage biopharmaceutical research and development company. In June 2025, SINORDA BIOMEDICINE closed a Series B funding from new investor Qiansheng Guozi. SINORDA BIOMEDICINE specializes in the development and commercialization of innovative biopharmaceutical products designed to address significant unmet medical needs. Its core product offerings include a range of therapeutic solutions targeting various diseases, particularly in oncology and autoimmune disorders.
These products utilize advanced biotechnological methods to enhance efficacy and improve patient outcomes. SINORDA's offerings are aimed at improving treatment protocols, thereby offering solutions that can lead to better health management in clinical settings. The company markets its products primarily in regions such as North America and Europe, where there is a high demand for cutting-edge biopharmaceutical therapies. SINORDA BIOMEDICINE generates revenue through a structured B2B model, primarily engaging with healthcare institutions, hospitals, and distribution partners.
Current Investors
Qiansheng Guozi
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Biotechnology, Pharmaceutical Research & Development
Website
www.sinorda.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.